NASDAQ:PASG - Passage Bio Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $13.20
  • Forecasted Upside: 547.06 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$2.04
▼ -0.12 (-5.56%)

This chart shows the closing price for PASG by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Passage Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PASG and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PASG

Analyst Price Target is $13.20
▲ +547.06% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Passage Bio in the last 3 months. The average price target is $13.20, with a high forecast of $24.00 and a low forecast of $6.00. The average price target represents a 547.06% upside from the last price of $2.04.

This chart shows the closing price for PASG for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 investment analysts is to buy stock in Passage Bio. This rating has held steady since January 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/14/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/15/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
8/13/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/11/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/9/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/10/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/9/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/8/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/5/2022Chardan CapitalLower Price Target$34.00 ➝ $18.00Low
8/5/2022CitigroupLower Price Target$10.00 ➝ $7.00Low
5/17/2022BTIG ResearchLower Price TargetNA$11.00Low
5/17/2022CitigroupLower Price TargetBuy$15.00 ➝ $10.00N/A
3/11/2022Chardan CapitalLower Price Target$43.00 ➝ $34.00Low
3/8/2022JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralHigh
3/4/2022Raymond JamesLower Price TargetOutperform$29.00 ➝ $24.00High
3/3/2022WedbushReiterated RatingOutperformHigh
1/19/2022The Goldman Sachs GroupDowngradeBuy ➝ Neutral$29.00 ➝ $6.00High
1/18/2022BTIG ResearchLower Price Target$25.00 ➝ $16.00High
11/5/2021BTIG ResearchReiterated RatingBuy$24.00High
7/1/2021Chardan CapitalReiterated RatingBuyMedium
6/30/2021Raymond JamesInitiated CoverageOutperform$29.00High
6/14/2021BTIG ResearchInitiated CoverageBuy$25.00Medium
3/8/2021Chardan CapitalBoost Price TargetBuy$35.50 ➝ $45.00High
3/4/2021The Goldman Sachs GroupUpgradeNeutral ➝ Buy$28.00 ➝ $30.00High
2/4/2021GuggenheimInitiated CoverageBuy$25.00High
1/25/2021WedbushInitiated CoverageOutperform$26.00Medium
1/4/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$25.00 ➝ $35.00N/A
12/11/2020Smith Barney CitigroupInitiated CoverageNeutral$2.21Low
11/12/2020Chardan CapitalReiterated RatingBuy$32.50Medium
8/14/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$25.00High
8/13/2020Chardan CapitalReiterated RatingBuy$32.50Low
6/25/2020The Goldman Sachs GroupDowngradeBuy ➝ Neutral$28.00High
5/11/2020Chardan CapitalReiterated RatingBuy$30.00 ➝ $32.50High
3/25/2020Chardan CapitalInitiated CoverageBuy$30.00High
3/24/2020JPMorgan Chase & Co.Initiated CoverageOverweight$25.00Medium
3/24/2020CowenInitiated CoverageOutperformMedium
3/24/2020The Goldman Sachs GroupInitiated CoverageBuy$27.00High
(Data available from 8/9/2017 forward)

News Sentiment Rating

0.36 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/10/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/9/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
3/11/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
4/10/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/10/2022
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/9/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/9/2022
  • 3 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
8/8/2022

Current Sentiment

  • 3 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Passage Bio logo
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Read More

Today's Range

Now: $2.04
Low: $2.04
High: $2.16

50 Day Range

MA: $2.26
Low: $1.77
High: $2.76

52 Week Range

Now: $2.04
Low: $1.57
High: $13.03

Volume

1,823 shs

Average Volume

205,492 shs

Market Capitalization

$111.10 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.06

Frequently Asked Questions

What sell-side analysts currently cover shares of Passage Bio?

The following Wall Street research analysts have issued stock ratings on Passage Bio in the last twelve months: BTIG Research, Chardan Capital, Citigroup Inc., JPMorgan Chase & Co., Raymond James, The Goldman Sachs Group, Inc., and Wedbush.
View the latest analyst ratings for PASG.

What is the current price target for Passage Bio?

5 Wall Street analysts have set twelve-month price targets for Passage Bio in the last year. Their average twelve-month price target is $13.20, suggesting a possible upside of 511.1%. Raymond James has the highest price target set, predicting PASG will reach $24.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $6.00 for Passage Bio in the next year.
View the latest price targets for PASG.

What is the current consensus analyst rating for Passage Bio?

Passage Bio currently has 2 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PASG will outperform the market and that investors should add to their positions of Passage Bio.
View the latest ratings for PASG.

What other companies compete with Passage Bio?

How do I contact Passage Bio's investor relations team?

Passage Bio's physical mailing address is TWO COMMERCE SQUARE 2001 MARKET STREET 28TH FLOOR, PHILADELPHIA PA, 19103. The company's listed phone number is 267-866-0311 and its investor relations email address is [email protected] The official website for Passage Bio is www.passagebio.com. Learn More about contacing Passage Bio investor relations.